{"id":"NCT03257865","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder","officialTitle":"A Multicenter, Randomized, Double-blind Trial of Brexpiprazole Versus Placebo for the Acute Treatment Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-19","primaryCompletion":"2019-01-22","completion":"2019-01-22","firstPosted":"2017-08-22","resultsPosted":"2020-01-02","lastUpdate":"2020-02-11"},"enrollment":333,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar I Disorder","Manic Episode"],"interventions":[{"type":"DRUG","name":"Brexpiprazole","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Brexpiprazole","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To demonstrate the efficacy of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in participants with a diagnosis of bipolar I disorder.","primaryOutcome":{"measure":"Change From Baseline In Young-Mania Rating Scale (YMRS) Score At Week 3","timeFrame":"Baseline, Week 3","effectByArm":[{"arm":"Brexpiprazole","deltaMin":-12.3,"sd":0.73},{"arm":"Placebo","deltaMin":-10.7,"sd":0.71}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.1011"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":17},"locations":{"siteCount":38,"countries":["United States","Croatia","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":162},"commonTop":["Headache","Akathisia","Constipation","Nausea","Insomnia"]}}